CL2008003201A1 - Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. - Google Patents
Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.Info
- Publication number
- CL2008003201A1 CL2008003201A1 CL2008003201A CL2008003201A CL2008003201A1 CL 2008003201 A1 CL2008003201 A1 CL 2008003201A1 CL 2008003201 A CL2008003201 A CL 2008003201A CL 2008003201 A CL2008003201 A CL 2008003201A CL 2008003201 A1 CL2008003201 A1 CL 2008003201A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitors
- pat1
- gaboxadol
- oat
- useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 2
- 101100139878 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ran1 gene Proteins 0.000 title abstract 2
- 229950004346 gaboxadol Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000019116 sleep disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000001727 in vivo Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composición farmacéutica que comprende gaboxadol o una sal del mismo, y uno más inhibidores de pat1 y/o uno o más inhibidores de oat, útil en el tratamiento de trastornos del sueño, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200701541 | 2007-10-29 | ||
DKPA200801198 | 2008-09-01 | ||
DKPA200801443 | 2008-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003201A1 true CL2008003201A1 (es) | 2009-10-16 |
Family
ID=40419047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003201A CL2008003201A1 (es) | 2007-10-29 | 2008-10-28 | Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090143335A1 (es) |
AR (1) | AR070516A1 (es) |
CL (1) | CL2008003201A1 (es) |
TW (1) | TW200924757A (es) |
WO (1) | WO2009056146A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3372229T3 (pl) | 2014-06-06 | 2021-10-04 | Ovid Therapeutics, Inc. | Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana |
KR20180031721A (ko) * | 2015-07-17 | 2018-03-28 | 오비드 테라퓨틱스 인크. | 가복사돌로 발달장애들을 치료하는 방법들 |
EP3334427A4 (en) * | 2015-08-11 | 2019-02-06 | Ovid Therapeutics, Inc. | METHODS OF SEDATION AND PARENTERAL COMPOSITION FOR USE IN INTENSIVE CARE |
WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
CN111201022A (zh) | 2017-08-04 | 2020-05-26 | 奥维德医疗公司 | 加波沙朵在治疗糖尿病及相关状况中的用途 |
CN112930182A (zh) | 2018-09-20 | 2021-06-08 | 奥维德医疗公司 | 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途 |
CN113395962A (zh) | 2018-11-21 | 2021-09-14 | Certego治疗公司 | 加波沙朵用于降低自杀风险和快速缓解抑郁症 |
CN113423399A (zh) * | 2018-12-17 | 2021-09-21 | 奥维德医疗公司 | 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途 |
US11364228B2 (en) | 2019-12-18 | 2022-06-21 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004025808D1 (de) * | 2003-06-25 | 2010-04-15 | Lundbeck & Co As H | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen |
US20050137222A1 (en) * | 2003-12-18 | 2005-06-23 | H. Lundbeck A/S | Treatment of insomnia in human patients |
-
2008
- 2008-10-17 US US12/253,879 patent/US20090143335A1/en not_active Abandoned
- 2008-10-20 TW TW097140127A patent/TW200924757A/zh unknown
- 2008-10-28 WO PCT/DK2008/050264 patent/WO2009056146A1/en active Application Filing
- 2008-10-28 AR ARP080104706A patent/AR070516A1/es unknown
- 2008-10-28 CL CL2008003201A patent/CL2008003201A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009056146A1 (en) | 2009-05-07 |
TW200924757A (en) | 2009-06-16 |
US20090143335A1 (en) | 2009-06-04 |
AR070516A1 (es) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003201A1 (es) | Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
AR073563A1 (es) | Terapia de combinacion para el tratamiento de diabetes y estados relacionados | |
CO6361942A2 (es) | Terapia de combinacion con epoxicetonas peptidicas | |
CO6361917A2 (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico | |
ATE551063T1 (de) | Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
EA202091999A2 (ru) | Применение ингибиторов dpp iv | |
CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
ECSP088786A (es) | Tratamientos de las alergias oculares | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
WO2010077339A3 (en) | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | |
CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
ES2723778T3 (es) | Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos |